Table 1 Baseline clinical characteristics of patients
Parameter | Entire cohort (n = 295) | Low Lp(a) group (n = 148) | High Lp(a) group (n = 147) | P |
|---|---|---|---|---|
Age, years (n = 295) | 58.69 ± 9.82 | 58.39 ± 10.47 | 58.99 ± 9.14 | 0.604 |
Male, % (n = 295) | 260(88.1) | 133(89.9) | 127(86.4) | 0.357 |
BMI, kg/m2 (n = 295) | 26.09 ± 3.33 | 26.47 ± 3.28 | 25.70 ± 3.35 | 0.097 |
Current smoker, % (n = 295) | 195(66.1) | 97(65.5) | 98(66.7) | 0.838 |
Hypertension, % (n = 295) | 165(55.9) | 87(58.8) | 78(53.1) | 0.322 |
Diabetes, % (n = 295) | 122(41.4) | 62(41.9) | 60(40.8) | 0.851 |
Hyperlipidemia, % (n = 295) | 278(94.2) | 140(94.6) | 138(93.9) | 0.792 |
Family history of CAD, % (n = 295) | 41(13.9) | 21(14.2) | 20(13.6) | 0.885 |
Previous stroke, % (n = 295) | 27(9.2) | 16(10.8) | 11(7.5) | 0.322 |
Peripheral vascular disease, % (n = 295) | 15(5.1) | 10(6.8) | 5(3.4) | 0.190 |
CKD, % (n = 295) | 26(8.8) | 10(6.8) | 16(10.9) | 0.211 |
ACS, % (n = 295) | 186(63.1) | 93(62.8) | 93(63.3) | 0.939 |
Psoriasis characteristics | ||||
 Psoriatic arthritis, % (n = 256) | 10(3.9) | 7(5.3) | 3(2.4) | 0.372 |
 Disease duration, years (n = 267) | 20(15, 30) | 20(15, 30) | 22.5(15, 30) | 0.814 |
 PASI score (n = 245) | 6.2(2.2, 13.25) | 5.5(1.1, 12.55) | 7.9(3.8, 13.5) | 0.500 |
 Topical treatment, % (n = 256) | 167(65.2) | 88(67.2) | 79(63.2) | 0.504 |
 Phototherapy, % (n = 256) | 33(12.9) | 18(13.7) | 15(12.0) | 0.678 |
 Nonbiologic systemic treatment, % (n = 256) | 105(41.0) | 53(40.5) | 52(41.6) | 0.853 |
 Biologic treatment, % (n = 256) | 27(10.5) | 12(9.2) | 15(12) | 0.460 |
Medication at discharge (n = 293) | ||||
 Aspirin, % | 271(92.5) | 138(93.2) | 133(91.7) | 0.622 |
 P2Y12 inhibitors, % | 238(81.2) | 119(80.4) | 119(82.1) | 0.715 |
 ACEIs/ARBs, % | 148(50.5) | 75(50.7) | 73(50.3) | 0.955 |
 β-blockers, % | 247(84.3) | 117(79.1) | 130(89.7) | 0.013 |
 Statin, % | 284(96.9) | 143(96.6) | 141(97.2) | 1.000 |
 Calcium channel blockers, % | 58(19.8) | 33(22.3) | 25(17.2) | 0.278 |